NIH R01 · 2025
Prodrug Formulations Create Sustained-Release Antiretrovirals
Abstract Long acting (LA) therapeutics offer real potential for improved regimen adherence and disease outcomes for chronic infectious diseases. For human immunodeficiency virus (HIV) infections only cabenuva has emerged as a sole complete LA regimen to affect long-term viral suppression. However, the requirements for every two- months dosing, injection site reactions, health care practitioner administration, high dosing volumes, and prolonged “tail phase” pharmacokinetic (PK) profiles are challenges for broad use. Ultra-LA (ULA) therapies are therefore obvious next step needs. Such ULA antiretroviral therapies (ART) would increase dose intervals to simplify treatment, limit emergence of…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.